BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31141164)

  • 1. NAMPT regulates PKM2 nuclear location through 14-3-3ζ: Conferring resistance to tamoxifen in breast cancer.
    Ge X; Zhao Y; Dong L; Seng J; Zhang X; Dou D
    J Cell Physiol; 2019 Dec; 234(12):23409-23420. PubMed ID: 31141164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2.
    Wei L; Li K; Pang X; Guo B; Su M; Huang Y; Wang N; Ji F; Zhong C; Yang J; Zhang Z; Jiang Y; Liu Y; Chen T
    J Exp Clin Cancer Res; 2016 Oct; 35(1):166. PubMed ID: 27769315
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
    Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
    [No Abstract]   [Full Text] [Related]  

  • 4. Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin.
    Bolandghamat Pour Z; Nourbakhsh M; Mousavizadeh K; Madjd Z; Ghorbanhosseini SS; Abdolvahabi Z; Hesari Z; Ezzati Mobasser S
    BMC Cancer; 2019 Nov; 19(1):1027. PubMed ID: 31675930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXO1 functions in the regulation of nicotinamide phosphoribosyltransferase (Nampt) expression.
    Jeong B; Park JW; Kim JG; Lee BJ
    Biochem Biophys Res Commun; 2019 Apr; 511(2):398-403. PubMed ID: 30799084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinamide phosphoribosyl transferase regulates cell growth via the Sirt1/P53 signaling pathway and is a prognosis marker in colorectal cancer.
    Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Qin L; Pan YL
    J Cell Physiol; 2019 Apr; 234(4):4385-4395. PubMed ID: 30191976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.
    Bergamaschi A; Katzenellenbogen BS
    Oncogene; 2012 Jan; 31(1):39-47. PubMed ID: 21666713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells.
    Phuong NT; Kim SK; Lim SC; Kim HS; Kim TH; Lee KY; Ahn SG; Yoon JH; Kang KW
    Breast Cancer Res Treat; 2011 Nov; 130(1):73-83. PubMed ID: 21170675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
    Hong SM; Park CW; Kim SW; Nam YJ; Yu JH; Shin JH; Yun CH; Im SH; Kim KT; Sung YC; Choi KY
    Oncogene; 2016 Jul; 35(27):3544-54. PubMed ID: 26568303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
    Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
    Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
    Okumura S; Sasaki T; Minami Y; Ohsaki Y
    J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
    Ojo D; Wu Y; Bane A; Tang D
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
    Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
    BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells.
    Li F; Miao L; Xue T; Qin H; Mondal S; Thompson PR; Coonrod SA; Liu X; Zhang X
    J Exp Clin Cancer Res; 2019 Oct; 38(1):414. PubMed ID: 31601253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
    Shah KN; Mehta KR; Peterson D; Evangelista M; Livesey JC; Faridi JS
    Mol Cancer Res; 2014 Mar; 12(3):394-407. PubMed ID: 24362250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
    Santidrian AF; LeBoeuf SE; Wold ED; Ritland M; Forsyth JS; Felding BH
    DNA Repair (Amst); 2014 Nov; 23():79-87. PubMed ID: 25263164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.
    Xie X; Huang X; Tang H; Ye F; Yang L; Guo X; Tian Z; Xie X; Peng C; Xie X
    Curr Cancer Drug Targets; 2018; 18(6):592-599. PubMed ID: 29110616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
    Soncini D; Caffa I; Zoppoli G; Cea M; Cagnetta A; Passalacqua M; Mastracci L; Boero S; Montecucco F; Sociali G; Lasigliè D; Damonte P; Grozio A; Mannino E; Poggi A; D'Agostino VG; Monacelli F; Provenzani A; Odetti P; Ballestrero A; Bruzzone S; Nencioni A
    J Biol Chem; 2014 Dec; 289(49):34189-204. PubMed ID: 25331943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.